Clinicopathologic and prognostic significance of serum levels of cytokines in patients with advanced serous ovarian cancer prior to surgery

Chinese Journal of Pathology

Volumn 39, Issue 10, 2010, Pages 666-670

  Zhu, Xin ^a   Ying, Li Sha ^b   Xu, Shen Hua ^b   Zhu, Chi Hong ^b   Xie, Jin Bo ^b  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b NONE

Author keywords

Interleukin 10; Interleukin 2; Ovarian neoplasms; Prognosis

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE; AGED; ARTICLE; BLOOD; CANCER STAGING; CYSTADENOCARCINOMA; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MENOPAUSE; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PREOPERATIVE PERIOD; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE;

ADULT; AGE FACTORS; AGED; CYSTADENOCARCINOMA, SEROUS; CYTOKINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-4; INTERLEUKIN-5; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MENOPAUSE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PREOPERATIVE PERIOD; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78549277498     PISSN: 05295807     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0529-5807.2010.10.005     Document Type: Article

References (27)

1. Lauerova L, Dušek L, Simickova M, et al. Malignant melanoma associates with Thl/Th2 imbalance that coincides with disease progression and immunotherapy response. Neoplasma, 2002, 49 (3): 159-166.
2. Okamoto T, Iwata S, Ohnuma K, et al. Histamine HI-receptor antagonists with immunomodulating activities; potential use for modulating T helper type 1 (Thl)/Th2 cytokine imbalance and inflammatory responses in allergic diseases. Clin Exp Immunol, 2009, 157(1): 27-34.
3. Kharkevitch DD, Seito D, Balch GC, et al. Characterization of autologous tumor-specific T-helper 2 cells in tumor-infiltrating lymphocytes from a patient with metastatic melanoma. Int J Cancer, 1994, 58(3): 317-323.
4. Kumar R, Kamdar D, Madden L, et al. Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients. Oncol Rep, 2006, 15(6): 1513-1516.
5. Matsuda A, Furukawa K, Takasaki H, et al. Preoperative oral immune-enhancing nutritional supplementation corrects TH1/TH2 imbalance in patients undergoing elective surgery for colorectal cancer. Dis Colon Rectum, 2006, 49(4): 507-516.
6. Chechliñska M, Duma A, Swierkowska K, et al. Sera of lung cancer patients affect the release of Th1, Th2 and monocytederived cytokines, and the expression of IL-2R alpha by normal, stimulated mononuclear cells. Cell Mol Biol Lett, 2004, 9 (1): 69-81.
7. Cao ZX, Chen XP, Wu ZD. Changes of immune function in patients with liver cirrhosis after splenectomy combined with resection of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int, 2003, 2(4): 562-565.
8. Luczyfiski W, Stasiak-Barmuta A, Krawczuk-Rybak M, et al. Thl/Th2 balance in acute lymphoblastic leukemia in children. Przegl Lek, 2004, 61(9): 919-923.
9. Chen LL, Ye F, Lü WC, et al. Evaluation of immune inhibitory cytokine profiles in epithelial ovarian carcinoma. J Obstet Gynaecol Res, 2009, 35(2): 212-218.
10. Kurte M, López M, Aguirre A, et al. A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC class I and Transporter associated with Antigen Processing 1/2 in human melanoma cells. J Immunol, 2004, 173 (3): 1731-1737.
11. Duletivć-Nacinović A, Stifter S, Marijié B, et al. Serum IL-6, IL-8, IL-10 and beta2-microglobulin in association with international prognostic index in diffuse large B cell lymphoma Tumori, 2008, 94(4): 511-517.
12. el-Far M, Fouda M, Yahya R,et al. Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin's lymphoma. J Physiol Biochem, 2004, 60(4): 253-258.
13. Lech-Maranda E, Bienvenu J, Michallet AS, et al. Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. Eur Cytokine Netw, 2006, 17(1): 60-66.
14. Naruke M, Abe Y, Hatanaka H, et al. Interleukin-10 expression is correlated with growth fraction in human non-small cell lung cancer xenografts. Int J Oncol, 2001, 18(6): 1213-1217.
15. Ikeguchi M, Hatada T, Yamamoto M, et al. Serum interleukin-6 and -10 levels in patients with gastric cancer. Gastric Cancer, 2009, 12(2): 95-100.
16. Bien E, Balcerska A, Adamkiewicz-Drozynska E, et al. Pre-treatment serum levels of interleukin-10, interleukin-12 and their ratio predict response to therapy and probability of event-free and overall survival in childhood soft tissue sarcomas, Hodgkin's lymphomas and acute lymphoblastic leukemias. Clin Biochem, 2009,42(10-11): 1144-1157.
17. Mustea A, Könsgen D, Braicu EI, et al. Expression of IL-10 in patients with ovarian carcinoma. Anticancer Res, 2006, 26(2C): 1715-1718.
18. Zakrzewska I, Poznański J. Serum levels of interleukin-10 in patients with ovarian carcinoma in response to chemotherapy. Przegl Lek, 2003, 60(1): 18-20.
19. Asao H, Fu XY. Interferon-gamma has dual potentials in inhibiting or promoting cell proliferation. J Biol Chem, 2000, 275 (2): 867-874.
20. Chan JK, Urban R, Cheung MK, et al. Ovarian cancer in younger vs older women: a population-based analysis. Br J Cancer, 2006, 95(10): 1314-1320.